Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington
Massachusetts
02421
United States
Tel: 781-860-8660
Fax: 781-861-0566
Website: http://www.cubist.com/
Email: ir@cubist.com
About Cubist Pharmaceuticals, Inc.
There’s something special about working at Cubist Pharmaceuticals.We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.
Cubist is a bio-pharmaceutical company focused on the research, commercial¬ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment. CUBICIN® , (daptomycin for injection), our marketed product, has been used in the treatment of more than an estimated 1.1 million patients with serious and sometimes life-threatening infections. CUBICIN has generated hundreds of millions of dollars in annual sales that helped propel Cubist into one of the Commonwealth's best-performing firms as evidenced by recent recognition. Cubist was ranked among Top Pharmas on the Scrip 100 List, while Forbes recently listed Cubist as one of 14 "Productivity Powerhouses." Cubist appeared in The Boston Globe's 2010 annual list of the "Top Places to Work" in Massachusetts (for the third consecutive year).
Mass High Tech announced that Cubist ranked 13th among the top 30 Fastest-Growing Public Technology Companies in New England for 2010 and was one of only ten pharmaceutical companies to make that list. Cubist also debuted as the 31st overall company and top pharmaceutical company named to FORTUNE's 2010 List of 100 Fastest-Growing Companies, and was named to the 2010 Deloitte Technology Fast 500™ for the sixth consecutive year.
357 articles about Cubist Pharmaceuticals, Inc.
-
Cubist Pharmaceuticals, Inc. Reports Second Quarter 2013 Financial Results
7/19/2013
-
Cubist Pharmaceuticals, Inc. Enrolls First Patient in Phase 3 Efficacy Studies Evaluating Bevenopran for the Treatment of Opioid-Induced Constipation
7/19/2013
-
Cubist Pharmaceuticals, Inc. to Present at Jefferies and Co. 2013 Global Healthcare Conference
5/24/2013
-
Cubist Pharmaceuticals, Inc. Achieves Top Biotech Ranking in Globe 100 List
5/20/2013
-
AstraZeneca PLC, Cubist Pharmaceuticals, Inc., Astellas Pharma Inc. Said to Make Bids for Optimer Pharmaceuticals, Inc.
5/15/2013
-
Cubist Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5/9/2013
-
FDA Grants Fast Track Designation for Cubist Pharmaceuticals, Inc.’s Late-Stage Antibiotic Candidate
5/7/2013
-
Cubist Pharmaceuticals, Inc. Reports First Quarter 2013 Financial Results
4/19/2013
-
Cubist Pharmaceuticals, Inc. to Announce First Quarter 2013 Financial Results on Thursday, April 18th, 2013
4/11/2013
-
Cubist Pharmaceuticals, Inc., Astellas Pharma Inc. Enter $25 Million Deal for Remaining Rights to Ceftolozane
3/11/2013
-
FDA Grants QIDP and Fast Track Designations for Cubist Pharmaceuticals, Inc.'s Late-Stage Antibiotic Candidates
3/1/2013
-
Cubist Pharmaceuticals, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
2/27/2013
-
Cubist Pharmaceuticals, Inc. to Present at February Investor Conferences
1/29/2013
-
Cubist Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results
1/24/2013
-
Cubist Pharmaceuticals, Inc. Announces Full-Year 2012 Revenues and Provides Business Update
1/7/2013
-
Cubist Pharmaceuticals, Inc. Submits ENTEREG Supplemental NDA
12/21/2012
-
FDA Grants QIDP Designation to Two Cubist Pharmaceuticals, Inc. Phase 3 Antibiotic Candidates
12/7/2012
-
Cubist Pharmaceuticals, Inc. to Present at December Investor Conference
12/3/2012
-
Cubist Pharmaceuticals, Inc. Named One of “Top Places to Work” by the Boston Globe for Fifth Consecutive Year
11/5/2012
-
Cubist Pharmaceuticals, Inc. to Present at November Investor Conferences
11/2/2012